Managing SNRI-Induced Drowsiness

Somnolence is a recognized adverse effect across the SNRI class, including duloxetine, venlafaxine, desvenlafaxine, and milnacipran, according to the American Academy of Child and Adolescent Psychiatry 1, 2
Fatigue and somnolence occur with moderate strength of evidence in SNRI-treated patients, as reported by the American Academy of Child and Adolescent Psychiatry 2
The symptom typically emerges within the first few weeks of treatment initiation, as noted by the American Academy of Child and Adolescent Psychiatry 3

Immediate Management Strategies

Move the dose to bedtime as the first-line intervention to leverage the sedating effect for sleep benefit rather than daytime impairment, as suggested by the American Academy of Clinical Endocrinologists 4
This strategy is particularly effective when somnolence is the primary tolerability concern, according to the American Academy of Child and Adolescent Psychiatry 1

Somnolence is a common adverse effect along with nausea, dizziness, and dry mouth, as reported by the American Academy of Child and Adolescent Psychiatry and the American Academy of Clinical Endocrinologists 1, 4
Immediate-release formulations of venlafaxine may cause more sedation due to peak-trough fluctuations requiring multiple daily doses, as noted by the American Academy of Child and Adolescent Psychiatry 1
Extended-release formulations of venlafaxine allow once-daily dosing and may have a more favorable tolerability profile, according to the American Academy of Child and Adolescent Psychiatry 1

SSRIs may cause less somnolence than SNRIs in some patients, though individual variation exists, as reported by the American Academy of Family Physicians and the American Academy of Child and Adolescent Psychiatry 3, 5
Bupropion is activating rather than sedating and may be preferred if sedation is problematic, though it lacks serotonergic activity, as noted by the American Academy of Family Physicians 5
For older adults with depression, consider sertraline, escitalopram, or bupropion as alternatives with favorable side effect profiles, according to the American Academy of Family Physicians 5

Monitor blood pressure and pulse as SNRIs can cause cardiovascular effects that may contribute to fatigue, as reported by the American Academy of Child and Adolescent Psychiatry 1
Evaluate for other contributing factors including sleep quality, comorbid conditions, and concomitant medications, as suggested by the American Academy of Family Physicians 5
Warn patients that somnolence may occur but often improves over 2-4 weeks, as noted by the American Academy of Child and Adolescent Psychiatry 3

The American Academy of Child and Adolescent Psychiatry recommends venlafaxine as a similar medication to desvenlafaxine, available in immediate-release and extended-release formulations, effective for depression and certain anxiety disorders, with a potential greater suicide risk than other SNRIs, and requiring tapering when stopping 6
The American Academy of Child and Adolescent Psychiatry suggests duloxetine as an FDA-approved SNRI for generalized anxiety disorder in children and adolescents 7 years and older, with simple dosing and efficacy demonstrated in painful diabetic peripheral neuropathy, and rare but serious adverse effects including hepatic failure and severe skin reactions 6

The Annals of Internal Medicine reports that evidence from multiple studies shows no significant differences in efficacy between various SNRIs or between SNRIs and SSRIs for treating major depressive disorder, with meta-analyses showing small effect sizes that are likely not clinically significant 7
The Annals of Internal Medicine indicates that when switching medications after initial treatment failure, about 25% of patients become symptom-free, with no significant difference between sustained-release bupropion, sertraline, and extended-release venlafaxine, and some small studies suggest greater response rates with venlafaxine than with other second-generation antidepressants in treatment-resistant depression 8

The Journal of the American Academy of Child and Adolescent Psychiatry states that all SNRIs carry a risk of suicidal thinking and behavior, gastrointestinal symptoms, and other common effects such as diaphoresis, dry mouth, dizziness, headache, tremor, insomnia, somnolence, decreased appetite, and weight loss, as well as cardiovascular effects like increased blood pressure and pulse 6
The Mayo Clinic Proceedings recommends considering an alternative SNRI if a patient has specific comorbidities that might benefit from a particular SNRI, such as duloxetine for neuropathic pain, and notes that duloxetine typically starts at 30 mg once daily for 1 week before increasing to 60 mg once daily to reduce nausea 9